

Gerald Chi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6401224/gerald-chi-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

65
papers

1,094
citations

16
h-index

31
g-index

104
ext. papers

1,410
ext. citations

6.4
avg, IF

4.4
L-index

#	Paper	IF	Citations
65	Early and late recurrent cardiovascular events among high-risk patients with an acute coronary syndrome: Meta-analysis of phase III studies and implications on trial design.. <i>Clinical Cardiology</i> , 2022 ,	3.3	2
64	Inverse relationship between body mass index and risk of venous thromboembolism among medically ill hospitalized patients: Observations from the APEX trial.. <i>Thrombosis Research</i> , 2022 , 211, 63-69	8.2	
63	Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis.. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 774418	5.4	1
62	Evaluation of Cardiac Troponin and Adverse Outcomes After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis. <i>Neurocritical Care</i> , 2021 , 1	3.3	1
61	COVID-19 infection complicated by Guillain-Barre Syndrome: a systematic review of clinical features, pathogenic mechanism, and respiratory failure. <i>Journal of Research in Clinical Medicine</i> , 2021 , 9, 34-34	0.4	
60	Clinical outcomes of pharmacological thromboprophylaxis among patients with intracerebral hemorrhage: Systematic review and meta-analysis. <i>Clinical Neurology and Neurosurgery</i> , 2021 , 212, 107066	2.9	2
59	Extended Thromboprophylaxis With Betrixaban or Rivaroxaban for Acutely Ill Hospitalized Medical Patients: Meta-Analysis of Prespecified Subgroups. <i>Critical Pathways in Cardiology</i> , 2021 , 20, 16-24	1.3	1
58	The Role of Interleukin-27 in Atherosclerosis: A Contemporary Review. <i>Cardiology</i> , 2021 , 146, 517-530	1.6	1
57	Current Opinion on the use of Direct Oral Anticoagulants for the Prophylaxis of Venous Thromboembolism among Medical Inpatients. <i>Therapeutics and Clinical Risk Management</i> , 2021 , 17, 471-487	2.9	1
56	COVID-19: A double threat to takotsubo cardiomyopathy and spontaneous coronary artery dissection?. <i>Medical Hypotheses</i> , 2021 , 146, 110410	3.8	7
55	Association between red blood cell distribution width and mortality and severity among patients with COVID-19: A systematic review and meta-analysis. <i>Journal of Medical Virology</i> , 2021 , 93, 2513-2522	19.7	20
54	Effect of azithromycin and hydroxychloroquine in patients hospitalized with COVID-19: Network meta-analysis of randomized controlled trials. <i>Journal of Medical Virology</i> , 2021 , 93, 6737-6749	19.7	4
53	COVID-19-associated coagulopathy: a concise review on pathogenesis and clinical implications. <i>Infezioni in Medicina</i> , 2021 , 29, 1-9	3.6	5
52	Machine learning to predict venous thrombosis in acutely ill medical patients. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 230-237	5.1	15
51	Procedural, clinical, and health status outcomes in chronic total coronary occlusion revascularization: Results from the PERSPECTIVE study. <i>Catheterization and Cardiovascular Interventions</i> , 2020 , 96, 567-576	2.7	4
50	The AngelMed Guardian System in the Detection of Coronary Artery Occlusion: Current Perspectives. <i>Medical Devices: Evidence and Research</i> , 2020 , 13, 1-12	1.5	1
49	Coronary artery tortuosity: a narrative review. <i>Coronary Artery Disease</i> , 2020 , 31, 187-192	1.4	10

48	Spontaneous coronary artery dissection managed with a conservative or revascularization approach: a meta-analysis. <i>Journal of Cardiovascular Medicine</i> , 2020 , 21, 42-50	1.9	9
47	Relation of White Blood Cell Count to Bleeding and Ischemic Events in Patients With Acute Coronary Syndrome (from the ATLAS ACS 2-TIMI 51 Trial). <i>American Journal of Cardiology</i> , 2020 , 125, 661-669	3	2
46	Venous Thromboembolism among Hospitalized Patients with COVID-19 Undergoing Thromboprophylaxis: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	53
45	Differential effect of ticagrelor on irreversible harms in diabetes. <i>Lancet, The</i> , 2020 , 396, 93	40	
44	Effect of Vitamins and Dietary Supplements on Cardiovascular Health. <i>Critical Pathways in Cardiology</i> , 2020 , 19, 153-159	1.3	2
43	Prognostic Value of Biomarkers in Cardiac Allograft Vasculopathy following Heart Transplantation: A Literature Review. <i>Cardiology</i> , 2020 , 145, 693-702	1.6	2
42	Spontaneous coronary artery dissection and its association with takotsubo syndrome: Novel insights from a tertiary center registry. <i>Catheterization and Cardiovascular Interventions</i> , 2020 , 95, 485-491	2.7	21
41	Chikungunya Virus Infection-related Rhabdomyolysis: A Case Report. <i>Cureus</i> , 2019 , 11, e4036	1.2	4
40	Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial. <i>TH Open</i> , 2019 , 3, e103-e108	2.7	1
39	Spontaneous coronary artery dissection and associated myocardial bridging: Current evidence from cohort study and case reports. <i>Medical Hypotheses</i> , 2019 , 128, 50-53	3.8	6
38	Risk Factors, Imaging Findings, and Sex Differences in Spontaneous Coronary Artery Dissection. <i>American Journal of Cardiology</i> , 2019 , 123, 1783-1787	3	34
37	Extended or shorter prophylaxis for venous thromboembolism in acutely ill hospitalized patients: Updated meta-analysis of randomized trials. <i>Vascular Medicine</i> , 2019 , 24, 156-158	3.3	5
36	Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients. <i>Circulation</i> , 2019 , 139, 1234-1236	16.7	4
35	Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. <i>Intensive Care Medicine</i> , 2019 , 45, 477-487	14.5	12
34	Smartwatch for the Detection of Atrial Fibrillation. <i>Critical Pathways in Cardiology</i> , 2019 , 18, 176-184	1.3	8
33	Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial. <i>American Journal of Hematology</i> , 2019 , 94, 21-28	7.1	28
32	Dual antithrombotic plus adjunctive antiinflammatory therapy to improve cardiovascular outcome in atrial fibrillation patients with concurrent acute coronary syndrome: A triple-pathway strategy. <i>Medical Hypotheses</i> , 2018 , 114, 40-44	3.8	4
31	Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy. <i>American Journal of Medicine</i> , 2018 , 131, 972.e1-972.e7	2.4	15

30	Intercellular adhesion molecule-1 in diabetic patients with and without microalbuminuria. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2018 , 12, 365-368	8.9	14
29	Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial). <i>Circulation</i> , 2018 , 137, 91-94	16.7	25
28	Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients. <i>American Heart Journal</i> , 2018 , 198, 84-90	4.9	16
27	Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 626-634	5	19
26	Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial. <i>TH Open</i> , 2018 , 2, e16-e24	2.7	6
25	Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the Apex Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial). <i>Circulation</i> , 2018 , 137, 91-94	3.2	
24	D-Dimer Levels and Effect of Rivaroxaban on Those Levels and Outcomes in Patients With Acute Coronary Syndrome (An ATLAS ACS-TIMI 46 Trial Substudy). <i>American Journal of Cardiology</i> , 2018 , 122, 1459-1464	3	13
23	Non-vitamin K antagonist oral anticoagulants for the treatment of intracardiac thrombosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 46, 332-338	5.1	6
22	Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial. <i>American Heart Journal</i> , 2018 , 203, 17-24	4.9	9
21	Effect of intensive versus standard blood pressure control on major adverse cardiac events and serious adverse events: A bivariate analysis of randomized controlled trials. <i>Clinical and Experimental Hypertension</i> , 2018 , 1-8	2.2	6
20	Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 2046-2052	7	28
19	Eosinophilic inflammation in spontaneous coronary artery dissection: A potential therapeutic target?. <i>Medical Hypotheses</i> , 2018 , 121, 91-94	3.8	13
18	Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism. <i>Expert Review of Cardiovascular Therapy</i> , 2018 , 16, 845-855	2.5	4
17	Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 46, 346-350	5.1	8
16	Scleral exposure alterations following Le Fort I osteotomy (with and without maxillary impaction) in skeletal class III patients: A before-and-after clinical trial. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2018 , 46, 1480-1483	3.6	1
15	The risk of stroke among acutely ill hospitalized medical patients: lessons from recent trials on extended-duration thromboprophylaxis. <i>Expert Review of Hematology</i> , 2017 , 10, 679-684	2.8	1
14	Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors. <i>Expert Review of Cardiovascular Therapy</i> , 2017 , 15, 237-245	2.5	10
13	Surface Microbiology of Smartphone Screen Protectors Among Healthcare Professionals. <i>Cureus</i> , 2017 , 9, e1989	1.2	5

12	N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. <i>Journal of Thrombosis and Thrombolysis</i> , 2017 , 44, 457-465	5.1	8
11	Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	30
10	Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2017 , 15, 1913-1922	15.4	16
9	The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. <i>TH Open</i> , 2017 , 1, e56-e65	2.7	62
8	Letter by Chi and Marszalek Regarding Article, "Composite End Points in Clinical Research: A Time for Reappraisal". <i>Circulation</i> , 2017 , 136, 2397-2398	16.7	2
7	Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. <i>Circulation</i> , 2017 , 135, 323-333	16.7	72
6	Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). <i>Circulation</i> , 2017 , 135, 648-655	16.7	46
5	Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 2389-2395 ⁷		18
4	Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial). <i>American Journal of Cardiology</i> , 2016 , 118, 625-31	3	6
3	Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. <i>New England Journal of Medicine</i> , 2016 , 375, 534-44	59.2	286
2	Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy. <i>Circulation: Cardiovascular Interventions</i> , 2016 , 9, e003114	6	12
1	D-Dimer elevation and adverse outcomes. <i>Journal of Thrombosis and Thrombolysis</i> , 2015 , 39, 55-9	5.1	45